Skip to main content
logo
Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025

Regulus Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
-----10.01
Revenue Growth
-----46.46%
Gross Profit
-36.15-35.37-21.15-18.41-17.79-5.34
Operating Income
-51.75-50.04-31.11-28.24-27.82-14.16
Net Income
-47.52-46.36-30.04-28.32-27.81-15.73
Earnings Per Share
-0.72-0.82-1.58-1.86-3.24-4.50
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
65.3775.7823.7739.1660.3831.09
Total Debt
1.41.063.16.937.685.13
Net Cash (Debt)
63.9774.7220.6732.2352.725.96
Net Cash Growth
-32.96%261.59%-35.89%-38.84%103.00%41.26%
Net Cash Per Share
0.971.331.092.116.157.42

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-43.54-41.67-26.77-25.53-24.13-12.54
Capital Expenditures
-0.11-0.34-0.61-0.36-0.25-
Free Cash Flow
-43.66-42.01-27.38-25.89-24.38-12.54
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingMar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
------53.38%
Operating Margin
------141.47%
Pretax Margin
------157.21%
Profit Margin
------157.21%
FCF Margin
------125.28%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
-----9.03